164. Timilshina M, You Z, Lacher SM, Acharya S, Jiang L, Kang Y, et al. Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells. *Cell Rep* (2019) 27(10):2948-61. doi: 10.1016/j.celrep.2019.05.020

165. Su X, Wang Q, Guo W, Pei X, Niu Q, Liu M, et al. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation. *Cell Mol Immunol* (2020) 17(5):483-95. doi: 10.1038/s41423-019-0312-3

166. Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. *Cell Metab* (2017) 25(6):1282-93.e7. doi: 10.1016/j.cmet.2016.12.018

167. He N, Fan W, Henriquez B, Yu RT, Atkins AR, Liddle C, et al. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. *Proc Natl Acad Sci USA* (2017) 114(47):12542-7. doi: 10.1073/pnas.1715363114

168. San Segundo D, Ruiz JC, Fernandez-Fresnedo G, Izquierdo M, Gomez-Alamillo C, Cacho E, et al. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients. *Transplant Proc 2006/11/14 Ed* (2006) 38(8):2391-3. doi: 10.1016/j.transproceed.2006.08.081

169. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). *Blood* (2009) 114 (23):4784-91. doi: 10.1182/blood-2009-07-230482

170. Amini L, Wagner DL, Rössler U, Zarrinrad G, Wagner LF, Vollmer T, et al. CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. *Mol Ther* (2021) 29 (1):32-46. doi: 10.1016/j.ymthe.2020.09.011

171. Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, et al. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. *Blood Adv* (2020) 4 (14):3357-67. doi: 10.1182/bloodadvances.2020001977

172. Kaeuferle T, Deisenberger L, Jablonowski L, Stief TA, Blaeschke F, Willier S, et al. CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation. *Mol Ther* (2020) 28 (9):1965-73. doi: 10.1016/j.ymthe.2020.06.002

173. Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. *Blood* (2009) 114(23):4792-803. doi: 10.1182/blood-2009-07-228387

174. Mahic M, Henjum K, Yaqub S, Bjørneth BA, Torgersen KM, Taskén K, et al. Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. *Eur J Immunol* (2008) 38(3):640-6. doi: 10.1002/eji.200737529

175. Zheng J, Liu Y, Qin G, Chan P-L, Mao H, Lam K-T, et al. Efficient Induction and Expansion of Human Alloantigen-Specific CD8 Regulatory T Cells from Naive Precursors by CD40-Activated B Cells. *J Immunol* (2009) 183 (6):3742-50. doi: 10.4049/jimmunol.0901329

176. Picarda E, Bézie S, Venturi V, Echasserieau K, Mérieau E, Delhumeau A, et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. *J Clin Invest* (2014) 124(6):2497-512. doi: 10.1172/JCI17533

177. Picarda E, Bézie S, Usero L, Ossart J, Besnard M, Halim H, et al. Cross-Reactive Donor-Specific CD8+ Tregs Efficiently Prevent Transplant Rejection. *Cell Reports* (2019) 29(13):4245-55.e6. doi: 10.1016/j.celrep.2019.11.106

178. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. *J Exp Med* (2004) 199(11):1455-65. doi: 10.1084/jem.20040139

179. Bézie S, Meistermann D, Boucault L, Kilens S, Zoppi J, Autrussseau E, et al. Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/- Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice. *Front Immunol* (2018) 8:2014. doi: 10.3389/fimmu.2017.02014

180. Adair PR, Kim YC, Zhang A-H, Yoon J, Scott DW. Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision. *Front Immunol* (2017) 8:1117. doi: 10.3389/fimmu.2017.01117

181. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci* (1989) 86(24):10024-8. doi: 10.1073/pnas.86.24.10024

182. Yeh W-I, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, et al. Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. *Front Immunol* (2017) 8:1313. doi: 10.3389/fimmu.2017.01313

183. Brocker T, Riedinger M, Karjalainen K. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. *Eur J Immunol* (1996) 26(8):1770-4. doi: 10.1002/eji.1830260816

184. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu P-Q, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. *Nat Med* (2012) 18(5):807-15. doi: 10.1038/nm.2700

185. Hull CM, Nickolay LE, Estorninho M, Richardson MW, Riley JL, Peakman M, et al. Generation of human islet-specific regulatory T cells by TCR gene transfer. *J Autoimmun* (2017) 79:63-73. doi: 10.1016/j.jaut.2017.01.001

186. Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, et al. TCR affinity and specificity requirements for human regulatory T-cell function. *Blood* (2012) 119(15):3420-30. doi: 10.1182/blood-2011-09-377051

187. Beringer DX, Kleijwegt FS, Wiede F, van der Slik AR, Loh KL, Petersen J, et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. *Nat Immunol* (2015) 16(11):1153-61. doi: 10.1038/ni.3271

188. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. *Cancer Res* (2015) 75(17):3596-607. doi: 10.1158/0008-5472.CAN-15-0159

189. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. *Cancer Res* (2015) 75 (17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139

190. Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J Clin Invest* (2016) 126(6):2123-38.

191. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunol Res* (2013) 1:26-31.

192. Akatsuka Y. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens. *Front Immunol* (2020) 11:257. doi: 10.3389/fimmu.2020.00257

193. Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, et al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. *J Autoimmun* 2018/03/06 *Ed* (2018) 90:116-31. doi: 10.1016/j.jaut.2018.02.006

194. Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. *Nat Biotechnol* (2017) 35(8):765-72. doi: 10.1038/nbt.3860

195. Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nat Biotechnol* (2019) 37(3):252-8. doi: 10.1038/s41587-019-0016-3

196. Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell* (2009) 138(2):271-85. doi: 10.1016/j.cell.2009.05.046

197. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood* (2016) 127(8):1044-51.

198. Brandt LJB, Barnkob MB, Michaels YS, Heiselberg J, Barington T. Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review. *Front Immunol* (2020) 11:326. doi: 10.3389/fimmu.2020.00326

199. Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon T, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. *J Immunol* (2009) 182(11):6879-88. doi: 10.4049/jimmunol.0803670

200. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. *Nat Biotechnol* (2013) 31 (10):928-33. doi: 10.1038/nbt.2678
164. Timilshina M, You Z, Lacher SM, Acharya S, Jiang L, Kang Y, et al. Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells. *Cell Rep* (2019) 27(10):2948-61. doi: 10.1016/j.celrep.2019.05.020

165. Su X, Wang Q, Guo W, Pei X, Niu Q, Liu M, et al. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation. *Cell Mol Immunol* (2020) 17(5):483-95. doi: 10.1038/s41423-019-0312-3

166. Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. *Cell Metab* (2017) 25(6):1282-93.e7. doi: 10.1016/j.cmet.2016.12.018

167. He N, Fan W, Henriquez B, Yu RT, Atkins AR, Liddle C, et al. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. *Proc Natl Acad Sci USA* (2017) 114(47):12542-7. doi: 10.1073/pnas.1715363114

168. San Segundo D, Ruiz JC, Fernandez-Fresnedo G, Izquierdo M, Gomez-Alamillo C, Cacho E, et al. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients. *Transplant Proc 2006/11/14 Ed* (2006) 38(8):2391-3. doi: 10.1016/j.transproceed.2006.08.081

169. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). *Blood* (2009) 114 (23):4784-91. doi: 10.1182/blood-2009-07-230482

170. Amini L, Wagner DL, Rössler U, Zarrinrad G, Wagner LF, Vollmer T, et al. CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. *Mol Ther* (2021) 29 (1):32-46. doi: 10.1016/j.ymthe.2020.09.011

171. Basar R, Daher M, Uprety N, Gokdemir E, Alsaliman A, Ensley E, et al. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. *Blood Adv* (2020) 4 (14):3357-67. doi: 10.1182/bloodadvances.2020001977

172. Kaeuferle T, Deisenberger L, Jablonowski L, Stief TA, Blaeschke F, Willier S, et al. CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation. *Mol Ther* (2020) 28 (9):1965-73. doi: 10.1016/j.ymthe.2020.06.002

173. Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. *Blood* (2009) 114(23):4792-803. doi: 10.1182/blood-2009-07-228387

174. Mahic M, Henjum K, Yaqub S, Bjørneth BA, Torgersen KM, Taskén K, et al. Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. *Eur J Immunol* (2008) 38(3):640-6. doi: 10.1002/eji.200737529

175. Zheng J, Liu Y, Qin G, Chan P-L, Mao H, Lam K-T, et al. Efficient Induction and Expansion of Human Alloantigen-Specific CD8 Regulatory T Cells from Naive Precursors by CD40-Activated B Cells. *J Immunol* (2009) 183 (6):3742-50. doi: 10.4049/jimmunol.0901329

176. Picarda E, Bézie S, Venturi V, Echasserieau K, Mérieau E, Delhumeau A, et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. *J Clin Invest* (2014) 124(6):2497-512. doi: 10.1172/JCI17533

177. Picarda E, Bézie S, Usero L, Ossart J, Besnard M, Halim H, et al. Cross-Reactive Donor-Specific CD8+ Tregs Efficiently Prevent Transplant Rejection. *Cell Reports* (2019) 29(13):4245-55.e6. doi: 10.1016/j.celrep.2019.11.106

178. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. *J Exp Med* (2004) 199(11):1455-65. doi: 10.1084/jem.20040139

179. Bézie S, Meistermann D, Boucault L, Kilens S, Zoppi J, Autrussseau E, et al. Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/- Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice. *Front Immunol* (2018) 8:2014. doi: 10.3389/fimmu.2017.02014

180. Adair PR, Kim YC, Zhang A-H, Yoon J, Scott DW. Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision. *Front Immunol* (2017) 8:1117. doi: 10.3389/fimmu.2017.01117

181. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci* (1989) 86(24):10024-8. doi: 10.1073/pnas.86.24.10024

182. Yeh W-I, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, et al. Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. *Front Immunol* (2017) 8:1313. doi: 10.3389/fimmu.2017.01313

183. Brocker T, Riedinger M, Karjalainen K. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. *Eur J Immunol* (1996) 26(8):1770-4. doi: 10.1002/eji.1830 260816

184. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu P-Q, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. *Nat Med* (2012) 18(5):807-15. doi: 10.1038/nm.2700

185. Hull CM, Nickolay LE, Estorninho M, Richardson MW, Riley JL, Peakman M, et al. Generation of human islet-specific regulatory T cells by TCR gene transfer. *J Autoimmun* (2017) 79:63-73. doi: 10.1016/j.jaut.2017.01.001

186. Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, et al. TCR affinity and specificity requirements for human regulatory T-cell function. *Blood* (2012) 119(15):3420-30. doi: 10.1182/blood-2011-09- 377051

187. Beringer DX, Kleijwegt FS, Wiede F, van der Slik AR, Loh KL, Petersen J, et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. *Nat Immunol* (2015) 16(11):1153-61. doi: 10.1038/ni.3271

188. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. *Cancer Res* (2015) 75(17):3596- 607. doi: 10.1158/0008-5472.CAN-15-0159

189. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. *Cancer Res* (2015) 75 (17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139

190. Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J Clin Invest* (2016) 126(6):2123-38.

191. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunol Res* (2013) 1:26-31.

192. Akatsuka Y. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens. *Front Immunol* (2020) 11:257. doi: 10.3389/ fimmu.2020.00257

193. Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, et al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. *J Autoimmun* 2018/03/06 *Ed* (2018) 90:116-31. doi: 10.1016/j.jaut.2018.02.006

194. Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. *Nat Biotechnol* (2017) 35(8):765-72. doi: 10.1038/nbt.3860

195. Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nat Biotechnol* (2019) 37(3):252-8. doi: 10.1038/s41587-019-0016-3

196. Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell* (2009) 138(2):271-85. doi: 10.1016/ j.cell.2009.05.046

197. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood* (2016) 127(8):1044-51.

198. Brandt LJB, Barnkob MB, Michaels YS, Heiselberg J, Barington T. Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review. *Front Immunol* (2020) 11:326. doi: 10.3389/fimmu.2020.00326

199. Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon T, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. *J Immunol* (2009) 182(11):6879-88. doi: 10.4049/jimmunol.0803670

200. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. *Nat Biotechnol* (2013) 31 (10):928-33. doi: 10.1038/nbt.2678
201. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. *Sci Transl Med* (2015) 7(315):315ra189. doi: 10.1126/scitranslmed.aad4134

202. Sharif-Paghaleh E, Sunassee K, Tavaré R, Ratnasothy K, Koers A, Ali N, et al. In Vivo SPECT Reporter Gene Imaging of Regulatory T Cells. *Zimmer J*, editor. *PloS One* (2011) 6(10):e25857. doi: 10.1371/journal.pone.0025857

203. Raffin C, Zhou Y, Piccoli L, Lanzavecchia A, Sadelain M, Tareen SU, et al. Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis. *J Immunol* (2018) 200(1 Supplement):176.17.

204. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A Special Population of Regulatory T Cells Potentiates Muscle Repair. *Cell* (2013) 155(6):1282-95. doi: 10.1016/j.cell.2013.10.054

205. Dombrowski Y, O'Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, et al. Regulatory T cells promote myelin regeneration in the central nervous system. *Nat Neurosci* (2017) 20(5):674-80. doi: 10.1038/nn.4528

206. Nosbaum A, Prevel N, Truong H-A, Mehta P, Ettinger M, Scharschmidt TC, et al. Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. *J Immun* (2016) 196(5):2010-4. doi: 10.4049/jimmunol.1502139

207. Zacchigna S, Martinelli V, Moimas S, Colliva A, Anzini M, Nordio A, et al. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction. *Nat Commun* (2018) 9 (1):2432. doi: 10.1038/s41467-018-04908-z

208. Schlundt C, Reinke S, Geissler S, Bucher CH, Giannini C, Märdian S, et al. Individual Effector/Regulator T Cell Ratios Impact Bone Regeneration. *Front Immunol* (2019) 10:1954. doi: 10.3389/fimmu.2019.01954

209. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from

defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. *Leukemia* (2016) 30(2):492-500. doi: 10.1038/leu.2015.247

210. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. *Cell* (2016) 167(2):419-432.e16. doi: 10.1016/j.cell.2016.09.011

211. Adigbli G, Ménoret S, Cross AR, Hester J, Issa F, Anegon I. Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease and Regenerative Medicine. *Transplantation* (2020) 104(11):2290-306. doi: 10.1097/TP.0000000000003177

212. Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, et al. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. *ALTEX* (2020) 37(3):365-94. doi: 10.14573/altex.2001241

**Conflict of Interest:** CG, IA, and SB have patents that have been licensed to TxCell S.A., a Sangamo Company. DW, LA, PR, H-DV, and MS-H have filed patent applications on Treg-related diagnostics and therapeutics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Amini, Greig, Schmueck-Henneresse, Volk, Bézie, Reinke, Guillonneau, Wagner and Anegon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
201. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. *Sci Transl Med* (2015) 7(315):315ra189. doi: 10.1126/scitranslmed.aad4134

202. Sharif-Paghaleh E, Sunassee K, Tavaré R, Ratnasothy K, Koers A, Ali N, et al. In Vivo SPECT Reporter Gene Imaging of Regulatory T Cells. *Zimmer J*, editor. *PloS One* (2011) 6(10):e25857. doi: 10.1371/journal.pone.0025857

203. Raffin C, Zhou Y, Piccoli L, Lanzavecchia A, Sadelain M, Tareen SU, et al. Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis. *J Immunol* (2018) 200(1 Supplement):176.17.

204. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A Special Population of Regulatory T Cells Potentiates Muscle Repair. *Cell* (2013) 155(6):1282-95. doi: 10.1016/j.cell.2013.10.054

205. Dombrowski Y, O'Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, et al. Regulatory T cells promote myelin regeneration in the central nervous system. *Nat Neurosci* (2017) 20(5):674-80. doi: 10.1038/nn.4528

206. Nosbaum A, Prevel N, Truong H-A, Mehta P, Ettinger M, Scharschmidt TC, et al. Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. *J Immun* (2016) 196(5):2010-4. doi: 10.4049/jimmunol.1502139

207. Zacchigna S, Martinelli V, Moimas S, Colliva A, Anzini M, Nordio A, et al. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction. *Nat Commun* (2018) 9 (1):2432. doi: 10.1038/s41467-018-04908-z

208. Schlundt C, Reinke S, Geissler S, Bucher CH, Giannini C, Märdian S, et al. Individual Effector/Regulator T Cell Ratios Impact Bone Regeneration. *Front Immunol* (2019) 10:1954. doi: 10.3389/fimmu.2019.01954

209. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from

defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. *Leukemia* (2016) 30(2):492-500. doi: 10.1038/leu.2015.247

210. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. *Cell* (2016) 167(2):419-432.e16. doi: 10.1016/j.cell.2016.09.011

211. Adigbli G, Ménoret S, Cross AR, Hester J, Issa F, Anegon I. Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease and Regenerative Medicine. *Transplantation* (2020) 104(11):2290-306. doi: 10.1097/TP.0000000000003177

212. Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, et al. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. *ALTEX* (2020) 37(3):365-94. doi: 10.14573/altex.2001241

**Conflict of Interest:** CG, IA, and SB have patents that have been licensed to TxCell S.A., a Sangamo Company. DW, LA, PR, H-DV, and MS-H have filed patent applications on Treg-related diagnostics and therapeutics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Amini, Greig, Schmueck-Henneresse, Volk, Bézie, Reinke, Guillonneau, Wagner and Anegon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.